|
| Thursday, 26 September 2019, 13:08 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Sept 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019. The Coroban predicts inpatients' tumbling and falling risks in advance and displays alerts.
Through the launch of antiosteoporotic agent and insomnia treatment, a pharmaceutical company Eisai has recognized that the preventive measures for tumbling and falling at medical institutions are important. On the other hand, FRONTEO Healthcare, Inc., a wholly owned subsidiary of FRONTEO, is a data analysis corporation focused on healthcare. It has originally developed an artificial intelligence (AI) system called Concept Encoder based on natural language processing technique.
Eisai and FRONTEO have started the joint development for the Coroban since January 2018. The Coroban was introduced to several medical institutions in Japan on a trial basis by leveraging Eisai's network with medical institutions, and advancing the improvements of Coroban based on needs in the clinical settings has led to the launch of the Coroban this time.
According to a survey by the Ministry of Health, Labour and Welfare, the number of inpatients aged 65 and over tends to increase to about 960,000 in 2017, therefore, the importance of cares for tumbling and falling in medical institutions is increasing. The Coroban learns the nursing records of past inpatients at each medical institution, scores the tumbling and falling risks of individual inpatient from the daily nursing records based on these past records, and displays the information of inpatients with high risks. It is expected to reduce the burden of medical professionals and to make the risk assessment uniform and objective by reflecting the information in individual care and nursing plans for each patient's tumbling and falling with the Coroban.
Through the launch of the Coroban which supports to establish systems at nursing ward to reduce the tumbling and falling risks of inpatients, Eisai and Fronteo aim to contribute to the realization of well-being of patients and their families.
About the tumbling and falling prediction system Coroban
Product name: Tumbling and Falling Prediction System Coroban
* The Coroban is not a medical device.
About Concept Encoder AI system
Concept Encoder is the AI system developed by FRONTEO Healthcare. Inc. specifically for the healthcare industry. The system was developed with the aim of effective, evidence-based analysis and utilization of healthcare-related big data, including large bodies of free-entry text data. The program incorporates significance tests and other crucial statistical methods for evidence-based medicine (EBM), the gold standard of practice among healthcare professionals, and applies this to natural language analysis. For more information, visit https://www.fronteo- healthcare.com/conceptencoder.
About FRONTEO, Inc. and FRONTEO Healthcare, Inc.
FRONTEO, Inc. supports the analysis of big data based on behavior informatics by utilizing its originally developed AI technology, "KIBIT". FRONTEO was found in 2003, and has ever since been developing our business primarily in the field of LegalTech including "eDiscovery" (preserve, process review, and analyze electronically stored data that could be evidence doe litigation process) and "digital forensics", as well as initiatives "Securely Identify Risks and Opportunities Buried in Records" in the field of business intelligence. FRONTEO Healthcare, Inc. was found in 2015. Through its data analysis capability, FRONTEO Healthcare, Inc. hopes to support people around the world in receiving the best healthcare services and pave the way to a healthier, more secure future.
For more information about FRONTEO, Inc. and FRONTEO Healthcare, Inc., please visit http://www.fronteo.com/ http://www.fronteo-healthcare.com/
Contact:
Media Inquiries:
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| July 31, 2025 17:27 HKT/SGT |
|
Revenue of LEQEMBI(R) (Preliminary Basis) |
| July 31, 2025 08:30 HKT/SGT |
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
| July 31, 2025 08:20 HKT/SGT |
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
| July 31, 2025 08:10 HKT/SGT |
|
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 |
| July 29, 2025 08:01 HKT/SGT |
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| July 25, 2025 12:31 HKT/SGT |
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| July 23, 2025 09:07 HKT/SGT |
|
Launch of Beova(R) Tablets in Thailand for Overactive Bladder |
| July 22, 2025 10:56 HKT/SGT |
|
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 |
| July 16, 2025 13:50 HKT/SGT |
|
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab |
| July 14, 2025 09:20 HKT/SGT |
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout |
| More news >> |
 |
|
|
|
